GSK In 'Countdown Mode' To Consumer Split As Full Year Sales Slip Back
Two months on from GSK’s rejection of a £50bn bid for Consumer Healthcare from Unilever – and with other suitors seemingly yet to materialize – CEO Emma Walmsley is pressing ahead with the plan to spin off the business in mid-2022. GSK will be buoyed by a strong showing by Consumer Healthcare in Q4, even through full year sales were down slightly.
You may also be interested in...
Immune-supplement brand Emergen-C has expanded its botanicals line to include pandemic-popular herbal ingredients apple cider vinegar and ashwagandha.
Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.
EU Business News: GSK Consumer Gets New Name, Navamedic Strikes Ipsen Deal, Enzymatica Optimistic After Tough Year
Round-up of the latest European consumer health business news: GSK reveals name for standalone consumer health business will be Haleon; Norways' Navamedic strikes a distribution deal with Ipsen for select GI OTC products; and Sweden's Enzymatica hopeful that changed consumer behaviors will help its sales rebound in 2022.